Guardant Health (GH:NSD) experienced a 26.9% decrease in holdings by Nuveen Asset Management LLC in the third quarter, according to its most recent Securities & Exchange Commission filing. The institutional investor sold 193,845 shares of GH, leaving the remaining 526,384 shares worth $28,336,000. Other institutional investors and hedge funds also made changes to their positions in the company, with 90.43% of Guardant Health stock currently owned by such entities.
Guardant Health Stock Forecast:
Despite the decrease in holdings, GH saw a 1.8% increase in stock value. GH’s market capitalization is currently at $3.17 billion with a price-to-earnings ratio of -4.83 and a beta of 0.86.
Based on GH stock forecast from 20 analysts, the average analyst target price for Guardant Health Inc is USD 65.20 over the next 12 months. Guardant Health Inc’s average analyst rating is Strong Buy.
Stock Target Advisor’s own stock analysis of Guardant Health Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, GH stock price was USD 30.89. Guardant Health price has changed by +13.78% over the past week, -1.86% over the past month, and -53.39% over the last year.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
It offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kit fulfillment-related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Palo Alto, California.